A total of 86.7% of patients received at least one line of systemic therapy before anti‐PD‐1/PDL‐1 treatment, 12 of them received platinum‐based doublet chemotherapy and one patient with MET amplified tumor received crizotinib. Here, CD274 is linked to neoplasm.